These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 37018468)

  • 21. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial.
    Cunningham S; Piedra PA; Martinon-Torres F; Szymanski H; Brackeva B; Dombrecht E; Detalle L; Fleurinck C;
    Lancet Respir Med; 2021 Jan; 9(1):21-32. PubMed ID: 33002427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Local and Systemic Immunity against Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine. A Randomized, Double-Blind, Placebo-controlled Clinical Trial.
    Ascough S; Vlachantoni I; Kalyan M; Haijema BJ; Wallin-Weber S; Dijkstra-Tiekstra M; Ahmed MS; van Roosmalen M; Grimaldi R; Zhang Q; Leenhouts K; Openshaw PJ; Chiu C
    Am J Respir Crit Care Med; 2019 Aug; 200(4):481-492. PubMed ID: 30753101
    [No Abstract]   [Full Text] [Related]  

  • 24. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
    Green CA; Sande CJ; Scarselli E; Capone S; Vitelli A; Nicosia A; Silva-Reyes L; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Hutchings CL; Cargill T; Angus B; Klenerman P; Pollard AJ
    J Infect; 2019 May; 78(5):382-392. PubMed ID: 30742894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial.
    O'Brien KL; Chandran A; Weatherholtz R; Jafri HS; Griffin MP; Bellamy T; Millar EV; Jensen KM; Harris BS; Reid R; Moulton LH; Losonsky GA; Karron RA; Santosham M;
    Lancet Infect Dis; 2015 Dec; 15(12):1398-408. PubMed ID: 26511956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant.
    Falloon J; Ji F; Curtis C; Bart S; Sheldon E; Krieger D; Dubovsky F; Lambert S; Takas T; Villafana T; Esser MT
    Vaccine; 2016 May; 34(25):2847-54. PubMed ID: 27102821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines.
    Simoes EA; Tan DH; Ohlsson A; Sales V; Wang EE
    Vaccine; 2001 Dec; 20(5-6):954-60. PubMed ID: 11738763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
    Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
    Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study.
    Leroux-Roels G; De Boever F; Maes C; Nguyen TL; Baker S; Gonzalez Lopez A
    Vaccine; 2019 May; 37(20):2694-2703. PubMed ID: 30987852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Efficacy Endpoints for a Phase IIb Study of a Respiratory Syncytial Virus Vaccine in Older Adults Using Patient-Reported Outcomes With Laboratory Confirmation.
    Yu J; Powers JH; Vallo D; Falloon J
    Value Health; 2020 Feb; 23(2):227-235. PubMed ID: 32113628
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
    Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
    Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults.
    Sadoff J; De Paepe E; Haazen W; Omoruyi E; Bastian AR; Comeaux C; Heijnen E; Strout C; Schuitemaker H; Callendret B
    J Infect Dis; 2021 Feb; 223(4):699-708. PubMed ID: 32851411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Live-attenuated Vaccines Prevent Respiratory Syncytial Virus-associated Illness in Young Children.
    Karron RA; Atwell JE; McFarland EJ; Cunningham CK; Muresan P; Perlowski C; Libous J; Spector SA; Yogev R; Aziz M; Woods S; Wanionek K; Collins PL; Buchholz UJ
    Am J Respir Crit Care Med; 2021 Mar; 203(5):594-603. PubMed ID: 32871092
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
    Baden LR; El Sahly HM; Essink B; Kotloff K; Frey S; Novak R; Diemert D; Spector SA; Rouphael N; Creech CB; McGettigan J; Khetan S; Segall N; Solis J; Brosz A; Fierro C; Schwartz H; Neuzil K; Corey L; Gilbert P; Janes H; Follmann D; Marovich M; Mascola J; Polakowski L; Ledgerwood J; Graham BS; Bennett H; Pajon R; Knightly C; Leav B; Deng W; Zhou H; Han S; Ivarsson M; Miller J; Zaks T;
    N Engl J Med; 2021 Feb; 384(5):403-416. PubMed ID: 33378609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
    Hammitt LL; Dagan R; Yuan Y; Baca Cots M; Bosheva M; Madhi SA; Muller WJ; Zar HJ; Brooks D; Grenham A; Wählby Hamrén U; Mankad VS; Ren P; Takas T; Abram ME; Leach A; Griffin MP; Villafana T;
    N Engl J Med; 2022 Mar; 386(9):837-846. PubMed ID: 35235726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.
    August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF
    Vaccine; 2017 Jun; 35(30):3749-3759. PubMed ID: 28579233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.
    Stuart ASV; Virta M; Williams K; Seppa I; Hartvickson R; Greenland M; Omoruyi E; Bastian AR; Haazen W; Salisch N; Gymnopoulou E; Callendret B; Faust SN; Snape MD; Heijnen E
    J Infect Dis; 2022 Dec; 227(1):71-82. PubMed ID: 36259542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.
    Langley JM; Sales V; McGeer A; Guasparini R; Predy G; Meekison W; Li M; Capellan J; Wang E
    Vaccine; 2009 Sep; 27(42):5913-9. PubMed ID: 19651171
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
    Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
    Lancet Infect Dis; 2020 Jul; 20(7):851-863. PubMed ID: 32251641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.